(Q44706399)

5 December 2017

title

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine (English)

1 reference

5 December 2017

1 reference

1 reference

Derek Misurski

1

1 reference

5 December 2017

Maureen J Lage

series ordinal

2

1 reference

5 December 2017

Rosalind Fabunmi

series ordinal

3

1 reference

5 December 2017

Kristina S Boye

series ordinal

4

1 reference

5 December 2017

publication date

1 January 2009

1 reference

Applied Health Economics and Health Policy

5 December 2017

published in

1 reference

5 December 2017

volume

7

1 reference

5 December 2017

issue

4

1 reference

5 December 2017

page(s)

245-254

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256158

5 December 2017

exact match

0 references

cites work

Economic costs of diabetes in the U.S. In 2007.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Insulin glargine: long-acting basal insulin analog for improved metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Epidemiology, trends, and morbidities of obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Intentional weight loss and mortality among overweight individuals with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Is the use of insulin analogues cost-effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Prevalence and costs of major depression among elderly claimants with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Methods for analyzing health care utilization and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

The association between diabetes related medical costs and glycemic control: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256158

21 January 2018

Identifiers

DOI

10.1007/BF03256158

1 reference

5 December 2017

1 reference